Tetraphase Pharmaceuticals Added to NASDAQ Biotechnology Index
December 15 2017 - 8:00AM
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage
biopharmaceutical company developing novel antibiotics to treat
life-threatening multidrug-resistant (MDR) infections, today
announced that it has been selected for addition to the NASDAQ
Biotechnology Index® (NASDAQ:^NBI). The annual re-ranking of the
NASDAQ Biotechnology Index will become effective prior to U.S.
market open on Monday, December 18, 2017.
The NASDAQ Biotechnology Index is designed to track the
performance of a set of securities listed on The NASDAQ Stock
Market® (NASDAQ®) that are classified as either biotechnology or
pharmaceutical according to the Industry Classification Benchmark
(ICB). The NASDAQ Biotechnology Index is calculated under a
modified capitalization-weighted methodology and ranked on annual
basis. All securities in the NASDAQ Biotechnology Index are listed
on the NASDAQ Global Market or the NASDAQ Global Select Market, and
meet minimum market value and share volume requirements among other
criteria.
The NASDAQ Biotechnology Index is the basis for the iShares
NASDAQ Biotechnology Index(SM) Fund. In addition, options based on
the iShares NASDAQ Biotechnology Index Fund trade on various
exchanges. For more information about the NASDAQ Biotechnology
Index visit www.nasdaq.com.
About Tetraphase Pharmaceuticals,
Inc.Tetraphase is a clinical-stage biopharmaceutical
company using its proprietary chemistry technology to create novel
antibiotics for serious and life-threatening bacterial infections,
including those caused by many of the multidrug-resistant (MDR)
bacteria highlighted as urgent public health threats by the CDC.
Tetraphase has created more than 3,000 novel tetracycline analogs
using its proprietary technology platform. Tetraphase's pipeline
includes three antibiotic clinical candidates: eravacycline, which
is in phase 3 clinical trials, and TP-271 and TP-6076, which are in
phase 1 clinical trials. Please visit www.tphase.com for more
company information.
Investor Contacts:Argot PartnersMaeve
Conneighton206-899-4940maeve@argotpartners.com
Media Contact:Sam Brown Inc.Mike
Beyer312-961-2502Mikebeyer@sambrown.com
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024